Press Releases

Home/Press Releases

Oramed Pharmaceuticals and Oravax Medical to be Featured in Alliance Global Partners’ Grand Rounds: A Webinar in Biotech and Specialty Pharma

NEW YORK, April 21, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that CEO Nadav Kidron will be featured in a live webinar titled Grand Rounds: a Webinar [...]

2021-04-21T07:25:00+00:00Categories: Press Releases|Tags: |

Oramed Initiates Second Phase 3 Oral Insulin Study Under the FDA’s Approved Dual Concurrent Protocol

Patients screened in ORA-D-013-2 study which is recruiting 450 patients in 53 sites in the U.S., Europe and Israel NEW YORK, March 23, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced [...]

2021-03-23T08:51:00+00:00Categories: Press Releases|Tags: |

Oramed Forms a Joint Venture, Oravax Medical Inc., for the Development of Novel Oral COVID-19 Vaccines

The Oral Vaccine Successfully Produced Antibodies in a Preclinical Study After a Single Dose NEW YORK, March 19, 2021 /PRNewswire/ -- Good candidate for protection against COVID variants due to triple antigen targeting  Implications for potential ease of widescale distribution and administration anytime, anywhere for [...]

2021-03-19T08:40:00+00:00Categories: Press Releases|Tags: |

Oramed Reaches 25% Randomization in World’s First Phase 3 Oral Insulin Study Conducted Under FDA Approved Protocol

ORA-D-013-1 study is recruiting 675 patients through 75 clinical sites throughout the U.S. NEW YORK, March 16, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has enrolled [...]

2021-03-16T08:25:00+00:00Categories: Press Releases|Tags: |

Oramed to Present at H.C. Wainwright BioConnect 2021 Conference

NEW YORK, Jan. 7, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that CEO Nadav Kidron will present a company overview at the H.C. Wainwright BioConnect 2021 [...]

2021-01-07T08:40:00+00:00Categories: Press Releases|Tags: |

Oramed Initiates Phase 2 NASH Trial of Oral Insulin

NEW YORK, Dec. 2, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has screened the first patients in a global trial of its oral insulin capsule [...]

2020-12-02T08:25:00+00:00Categories: Press Releases|Tags: |